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Summary
Objective: Synovium-derived stem cells (SDSCs) have proven to be superior in cartilage regeneration compared with other sources of mes-
enchymal stem cells. We hypothesized that conventionally passaged SDSCs can be engineered in vitro into cartilage tissue constructs and
the engineered premature tissue can be implanted to repair allogeneic full-thickness femoral condyle cartilage defects without immune
rejection.
Methods: Synovial tissue was harvested from rabbit knee joints. Passage 3 SDSCs were mixed with ﬁbrin glue and seeded into non-woven
polyglycolic acid (PGA) mesh. After 1-month incubation with growth factor cocktails, the premature tissue was implanted into rabbit knees to
repair osteochondral defects with Collagraft as a bone substitute in the Construct group. Fibrin glue-saturated PGA/Collagraft composites
were used as a Scaffold group. The defect was left untreated as an Empty group.
Results: SDSCs were engineered in rotating bioreactor systems into premature cartilage, which displayed the expression of sulfated glycos-
aminoglycan (GAG), collagen II, collagen I, and macrophages. Six months after implantation with premature tissue, cartilage defects were full
of smooth hyaline-like cartilage with no detectable collagen I and macrophages but a high expression of collagen II and GAG, which were also
integrated with the surrounding native cartilage. The Scaffold and Empty groups were resurfaced with ﬁbrous-like and ﬁbrocartilage tissue,
respectively.
Conclusion: Allogeneic SDSC-based premature tissue constructs are a promising stem cell-based approach for cartilage defects. Although in
vitro data suggest that contaminated macrophages affected the quality of SDSC-based premature cartilage, effects of macrophages on in vivo
tissue regeneration and integration necessitate further investigation.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Once damaged, articular cartilage has only limited intrinsic
capacity for self-repair1,2. Although autologous chondrocyte
implantation (ACI) has some advantages, a general prob-
lem with this chondrocyte-based procedure in cartilage re-
pair is the quality of newly formed cartilage. For example,
implanted chondrocytes undergo hypertrophic differentia-
tion with subsequent ossiﬁcation3,4 and poor integration to
host tissue5,6. In contrast, it has been shown that immature
constructs using mesenchymal stem cells (MSCs) integrate
better and are more durable7e9. MSCs can regenerate not
only cartilage but also the underlying subchondral bone10
and are therefore able to resurface osteochondral defects
as well.
MSCs are characterized by their multipotentiality and
capacity for self-renewal11. The hypoimmunogenic nature
implies that MSCs can be used in allogeneic cell-based1Supported by a grant from the Musculoskeletal Transplant Foun-
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714therapy12,13. MSCs from different sources have exhibited
different properties in expansion capacity and multi-lineage
differentiation14. Synovium-derived stem cells (SDSCs) are
a promising source of stem cells for cartilage tissue engi-
neering because they display greater chondrogenic and
less osteogenic potential than MSCs derived from bone
marrow or periosteum15. They are also proven to be supe-
rior to other sources of MSCs such as adipose tissue and
muscle16e18. Under appropriate stimulation conditions,
they are able to migrate into articular cartilage defects and
subsequently undergo chondrogenic differentiation10,19.
Studies also show that the molecular proﬁle of SDSCs is
stable during in vitro expansion from passage 3 up to at
least passage 1020,21.
Imitating the involvement of growth factors in cartilage de-
velopment, our previous study characterized the properties
of SDSCs and deﬁned growth factor cocktails for maximal
cell proliferation and chondrogenic differentiation22. How-
ever, it is unknown whether SDSCs can be engineered
into cartilage-like tissue in bioreactor systems supple-
mented with growth factor cocktails. We also question if al-
logeneic SDSC-engineered premature tissue can be
implanted to repair full-thickness femoral condyle cartilage
defects without immune rejection. Although MSCs have
immune ‘‘privilege’’ and immunomodulatory capacity, the
implanted tissue constructs derived from allogeneic SDSCs
715Osteoarthritis and Cartilage Vol. 17, No. 6having partially differentiated into chondrocytes. Therefore,
we are unsure whether the differentiated MSCs still have
immunomodulatory properties.
We hypothesized that SDSCs can be engineered in vitro
into cartilage tissue constructs and allogeneic SDSC-engi-
neered premature tissue can be implanted to repair full-
thickness femoral condyle cartilage defects without immune
rejection. Our long-term goal is to engineer high-quality car-
tilage constructs using allogeneic SDSCs for the repair of
cartilage defects resulting from trauma and osteoarthritis.Materials and methodsSDSC ISOLATION AND CULTURERandom biopsies of synovial tissue were obtained aseptically from the
knees of two 8-month-old New Zealand white rabbits and pooled together
[Fig. 1(A)]. The synovial tissue was ﬁnely minced and digested at 37C for
30 min in phosphate-buffered saline (PBS) containing 0.1% trypsin and
then for 2 h in 0.1% solution of collagenase P in DMEM/10% fetal bovine
serum (FBS). After passing through a 70-mm nylon ﬁlter, the cells were col-
lected from the ﬁltrate by centrifugation. Cells were plated and cultured for 4
days in complete medium (DMEM/F12/10% FBS, 100 U/mL penicillin,
100 mg/mL streptomycin). Non-adherent cells were removed by a PBS
wash on days 2 and 4. After 90% conﬂuence, primary cells were trypsinized
and replated as passage 1. Passage 3 SDSCs were collected for this study
[Fig. 1(B)].IN VITRO ENGINEERED SDSC-BASED TISSUE CONSTRUCTSDegradable polyglycolic acid (PGA) scaffolds (a mesh of 15-mm ﬁbers
and 97% void volume; Synthecon, Houston, TX) were punched into
5-mm-diameter 2-mm-thick discs and sterilized with ethylene oxide, then
immersed in 100% ethanol, 70% ethanol, and PBS (without Ca2þ andFig. 1. Diagram illustrating research design. (A): Synovial tissue harvesting
construct. (F): Static culture (3 days). (G): Bioreactor culture (4 weeks). (H):
construct. (K): Fibrin glue-saturated Collagraft. (L): Scaffold groupMg2þ). In a centrifuge tube, 150 mL ﬁbrinogen (100 mg/mL in PBS, Sigma,
St. Louis, MO) [Fig. 1(C)], 140 mL PBS with cells, 5 mL thrombin (0.1 U/mL,
Sigma), and 5 mL CaCl2 (50 mM) were sequentially added. Then, 26 mL of
SDSC-gel mixture was pipetted onto a PGA disc [Fig. 1(D)] in a Petri
dish. This procedure resulted in a total of 56 ﬁbrin-PGA composites contain-
ing 2.6 106 cells per scaffold [Fig. 1(E)], corresponding to an initial seed-
ing density of 100 106 cells/mL. The dish with constructs was transferred
into an incubator for 10 min. Complete medium was then added to cover the
constructs.
After 1 h, the medium was replaced by chemically deﬁned medium (high-
glucose DMEM, 40 mg/mL proline, 100 nmol/L dexamethasone, 0.1 mmol/L
ascorbic acid 2-phosphate, 100 U/mL penicillin, 100 mg/mL streptomycin,
and 1 ITS Premix) supplemented with a proliferative growth factor cock-
tail (10 ng/mL transforming growth factor b1 [TGF-b1], 50 ng/mL basic ﬁbro-
blast growth factor [FGF-2], and 500 ng/mL insulin-like growth factor I [IGF-I])
for 3 days [Fig. 1(F)]22. The cell-ﬁbrin-PGA constructs were transferred to
a rotating bioreactor (Rotary Cell Culture System-4 (RCCS-4); Synthecon)
ﬁlled with chemically deﬁned medium supplemented by a differentiative
growth factor cocktail (10 ng/mL TGF-b1 and 500 ng/mL IGF-I) for 28 days
[Fig. 1(G)]22 The bioreactor rotation speed was adjusted to maintain the
growing constructs freely suspended in the rotating ﬂow. Forty-four tissue
constructs were harvested [Fig. 1(H)] for the analyses at days 0, 3, 15,
and 31. Another 12 1-month constructs were used for in vivo implantation.IN VIVO IMPLANTATION OF PREMATURE TISSUE FOR
CARTILAGE REPAIRThis project was approved by the Institutional Animal Care and Use Com-
mittee (IACUC) and conducted in compliance with the National Advisory
Committee for Laboratory Animal Research Guidelines. Eighteen New Zea-
land white rabbits (8-month-old males weighing 3.5e4.0 kg) (Covance, Den-
ver, PA) were used in this study. The rabbits were anesthetized with 5 mg/kg
xylazine (Phoenix Pharmaceutical, St. Joseph, MO) and 35 mg/kg ketamine
(Phoenix Pharmaceutical) intramuscularly and maintained with isoﬂuorane.
The knee joints were approached through medial parapatellar incisions
and the articular surfaces were exposed by lateral dislocation of the patellae.
Full-thickness osteochondral defects, 4 mm diameter 5 mm deep, were. (B): SDSCs. (C): Fibrin glue. (D): PGA disc. (E): Cell-ﬁbrin glue-PGA
Premature tissue construct. (I): Construct group. (J): Punched tissue
. (M): Fibrin glue-saturated PGA scaffold. (N): Empty group.
716 M. Pei et al.: Synovial cell-based cartilage repaircreated in the medial femoral condyles of both knees using a dental drill
(Henry Schein, Melville, NY) with a depth stop.
Our experimental design included three groups: ‘‘Construct’’, ‘‘Scaffold’’,
and ‘‘Empty’’. In the Construct group [Fig. 1(I)], 12 defects were ﬁlled ran-
domly with punched tissue constructs [Fig. 1(J)] with ﬁbrin glue-saturated
Collagraft (Zimmer, Warsaw, IN) as a bone substitute [Fig. 1(K)]. In the
Scaffold group [Fig. 1(L)], 12 defects were ﬁlled with ﬁbrin glue-saturated
PGA [Fig. 1(M)]/Collagraft composites. In the Empty group [Fig. 1(N)], 12
defects were left untreated. All rabbits were returned to their cages after
the operation and allowed to move freely. Animals were sacriﬁced by an in-
tracardiac puncture of Euthasol euthanasia solution (Fort Dodge Animal
Health, Fort Dodge, IA) at 3 weeks (n¼ 3) and 6 months (n¼ 15) after the
operation. The femoral condyles were isolated for histomorphological
analysis.HISTOLOGICAL ANALYSISTissue constructs (n¼ 3) were ﬁxed overnight at 4C in 4% paraformalde-
hyde in PBS. For the implantation study, the dissected distal femurs were
also decalciﬁed at 4C in 4% ethylene-diamine-tetra-acetic acid (EDTA)
solution on a shaker. Radiographs were used to evaluate the progress of de-
calciﬁcation. After decalciﬁcation, the samples were dehydrated with a gradi-
ent ethanol series, cleared with xylene, and embedded in parafﬁn blocks.
Sagittal sections were cut at 5 mm thickness. The sections were routinely
stained with hematoxylin and eosin (H&E). To differentiate between cartilage
and ﬁbrous tissue, combined Safranin-O/fast green staining was performed.
All evaluations were performed at the most central section of the halved
defect specimen to ensure unbiased analysis.
All samples were also immunostained with monoclonal antibodies against
collagen II (II-II6B3; DSHB, Iowa City, IA), collagen I (Abcam, Cambridge,
MA), and macrophage Ab-5 (Clone RAM11, Lab Vision, Fremont, CA). Im-
munohistochemical sections were deparafﬁnized using xylene and hydrated
through graded alcohols. The samples were pretreated with 1% hydrogen
peroxide and incubated for 30 min with 2 mg/mL testicular hyaluronidase in
PBS (pH 5) at 37C followed by another 30 min with 1.5% normal goat serum
and overnight at 4C with the primary antibody. After extensive washing with
PBS, a secondary antibody of biotinylated horse anti-mouse IgG (Vector,
Burlingame, CA) was placed on the sections for 30 min at room temperature.
Immunostaining was conducted with Vectastain ABC reagent (Vector)
followed by 3,30-diaminobenzidine (DAB) staining. Counterstaining was
performed with hematoxylin (Vector).SEMIQUANTITATIVE HISTOLOGICAL SCORINGTwo observers blinded to the treatment groups evaluated the sections ac-
cording to the histological grading scale23,24. Five categories, including cell
morphology, matrix staining, surface regularity, thickness of cartilage, and in-
tegration with adjacent host cartilage, were examined with a maximum score
of 14 being the poorest result. This evaluation was performed according to
the ‘‘Modiﬁed Histological Grading Score’’, which also included unﬁlled
defects25. The total scores were compared among experimental groups.BIOCHEMICAL ANALYSISTissue constructs (n¼ 4) from the in vitro bioreactor culture were digested
for 6 h at 60C with 125 mg/mL papain in PBE buffer (100 mmol/L phosphate,
10 mmol/L EDTA, pH 6.5) containing 10 mmol/L cysteine, using 100 mL en-
zyme per sample. To quantify cell density, the amount of deoxyribonucleic
acid (DNA) in the papain digests was measured using the Quant-iT Pico-
Green dsDNA Assay kit (Invitrogen, Carlsbad, CA) with a CytoFluor Se-
ries 4000 (Applied Biosystems, Foster City, CA). GAG content was
measured using dimethylmethylene blue dye (DMMB) and a Spectronic Bi-
oMate 3 Spectrophotometer (Thermo Scientiﬁc, Milford, MA)26.WESTERN BLOTTo assess collagen II expression, tissue constructs (n¼ 3) were lyophi-
lized, measured for dry weights, incubated using 50 mg dry sample per
15 mL 4 mol/L guanidine hydrochloride (Sigma) for 20 h at 4C, homoge-
nized, and digested with 0.6 mg/mL of pepsin (Sigma) per mL in 0.5 mol/L
acetic acid (Sigma) at 4C for 48 h at a 10:1 ratio of dry sample to pepsin
(mg/mg). The samples were centrifuged at 48,000 g for 1 h, and the super-
natant was lyophilized and dissolved in radioimmunoprecipitation assay
(RIPA, Pierce, Rockford, IL) buffer with protease inhibitors (Roche, Indianap-
olis, IN). To assess Sox 9 protein expression, the samples were homoge-
nized and dissolved in RIPA buffer with protease inhibitors. Total proteins
were quantiﬁed using BCA Protein Assay Kit (Pierce). The samples
were denatured and separated by NuPAGE Novex Bis-Tris Mini Gels (In-
vitrogen) in the XCell SureLock Mini-Cell (Invitrogen) at 120 V for 3 h at
4C. Bands were transferred onto a nitrocellulose membrane (Invitrogen)using XCell II Blot module (Invitrogen) at 15 V overnight at 4C. Nonspe-
ciﬁc binding was blocked with 5% nonfat milk in TBST (100 mmol/L Tris-
HCl, 0.9% NaCl, 1% Tween 20, pH 7.5) for 1 h. The membrane was
incubated with a primary monoclonal antibody in 1% nonfat milk in TBST
to collagen II (DSHB) or Sox 9 (Abcam) for 1 h at room temperature (b-actin
served as an internal control for Sox 9), followed by the secondary antibody
of horseradish peroxidase-conjugated goat anti-mouse (Pierce) for 40 min at
room temperature and exposure using SuperSignal West Femto Maximum
Sensitivity Substrate (Pierce) and CL-XPosure Film (Pierce). For semi-
quantitative analysis, bands were scanned (CanoScan8400F, Canon, Lake
Success, NY) and analyzed using NIH Image J software (US National Insti-
tutes of Health, Bethesda, MD).MECHANICAL TESTINGCompressive moduli of 1-month tissue constructs (n¼ 4) were deter-
mined in uniaxial stress-relaxation tests using a stepper motor-driven minia-
ture compression device manufactured in-house with a miniature 5 mm
DVRT (Microstrain, Burlington, VT) used as a displacement gage in its lin-
ear range26. In brief, discs 3 mm in diameter and 1.5 mm thick were punched
and trimmed from the central region of the construct. Discs were equilibrated
in PBS containing protease inhibitors, placed in a cylindrical conﬁning cham-
ber ﬁlled with PBS, mounted in a miniature stepper motor controlled material
testing machine, and compressed with a porous stainless steel platen. A 5%
strain was applied and the load was monitored until equilibrium was reached
followed by four 2% strain steps with stress relaxation between each. Data
were recorded at a sampling rate of 10 points/s over a time increment of
480 s. Constructs were considered to fully relax during this increment based
on a change in stress of less than 0.006 MPa over the ﬁnal 180 s. The equi-
librium modulus was then determined for each sample as the slope of the
best linear regression ﬁt (r2> 0.99) of the measured equilibrium stress vs
applied strain.STATISTICAL ANALYSISWe used a one-way analysis of variance (ANOVA) F test. Statistical anal-
ysis was performed with SPSS 13.0 statistical software (SPSS Inc., Chicago,
IL). P values less than 0.05 were considered statistically signiﬁcant.ResultsIN VITRO ENGINEERING OF SDSC-BASED TISSUE
CONSTRUCTS IN A BIOREACTORAfter digestion with papain, the tissue constructs were still
visible at days 0, 3, and 15, suggesting the presence of the
PGA scaffolds. At day 31, the constructs disappeared,
indicating complete degradation of the PGA scaffolds and
replacement with newly formed tissue [Fig. 2(A)]. Biochem-
ical analyses showed that DNA content per construct, an in-
dicator of cell number, decreased with time [Fig. 2(B)]. In
contrast, GAG content, a major matrix constituent associ-
ated with cartilage compressive stress, increased in
a time-dependent manner [Fig. 2(C)]. The ratio of GAG to
DNA, a chondrogenic differentiation index, increased over
time up to day 31 [Fig. 2(D)].
Our western-blot data [Fig. 2(E)] showed that collagen II,
another major matrix constituent associated with cartilage
tension, was not detectable at day 3. However, collagen
type II was detected at day 15 and increased rapidly until
day 31, which was consistent with GAG expression
[Fig. 2(C, D)]. After incubation in a differentiative growth fac-
tor cocktail supplemented bioreactor, tissue constructs at
day 3 expressed the highest levels of Sox 9, a key chondro-
genic transcription factor. With the maturation of tissue
constructs, the expression of Sox 9 decreased in a time-
dependent fashion.
Histology data [Fig. 2(F)] showed that day 31 constructs
were ﬁlled with chondrocyte-occupied lacunae surrounded
by Safranin O stained GAG [Fig. 2(f1)] and immunostained
collagen II [Fig. 2(f2)]. As an early stage marker of cartilage
development, collagen I was visible throughout the
constructs [Fig. 2(f3)]. In addition, macrophages (type
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Fig. 2. In vitro SDSC-based tissue constructs. After papain digestion, the digests (A) from each construct were analyzed for DNA content (B)
and GAG content (C). The chondrogenic index was shown as a ratio of GAG to DNA (D). Differences between time points are indicated as
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718 M. Pei et al.: Synovial cell-based cartilage repairA synovial cells) were detectable even after 28-day-differ-
entiation in a bioreactor [Fig. 2(f4)]. The mechanical proper-
ties of bioreactor-engineered tissue constructs were also
measured. Our data showed that the average equilibrium
modulus of four tissue constructs at day 31 was 0.27 MPa
[Fig. 2(G)], which is about one third of the native cartilage
value27.Fig. 3. Threeweeks after implantation, immunostainingwas performed for p
aswell asmacrophages (D, d1, d2, d3, F), andH&Estaining (E) for lymph cel
B2, F) as well as Empty group (C1, C2). Enlargements (d1, d2) are from Fig. 3
from Fig. 3(D, E), respectively, at the borderline between implanted CollaIN VIVO IMPLANTATION OF PREMATURE TISSUE FOR THE
REPAIR OF FULL-THICKNESS CARTILAGE DEFECTSThree weeks after implantation, compared to the Empty
group [Fig. 3(C2, C1)], there was abundant expression of col-
lagen II [Fig. 3(A2)] and less collagen I [Fig. 3(A1)] in the pe-
ripheral zone of the Construct group, which integrated wellrotein expression of collagen I (A1, B1, C1) and collagen II (A2, B2, C2)
ls (e1) inConstruct group (A1, A2, D, d1, d2, d3) andScaffold group (B1,
(D) in the implanted tissue constructs; and enlargements (d3, e1) are
graft and the surrounding native bone. All scale bars are 100 mm.
719Osteoarthritis and Cartilage Vol. 17, No. 6with the surrounding native cartilage [Fig. 3(A1, A2)]. In con-
trast, there was a barely detectable expression of collagen I
[Fig. 3(B1)] and collagen II [Fig. 3(B2)] in the Scaffold group.
Part of the composites disappeared, likely a result of scaffold
degradation. Immunostaining demonstrated that there were
plenty of macrophages [Fig. 3(D)] located on both sides
[Fig. 3(d1, d2)] of the implanted tissue constructs and at the
interface between ﬁbrin glue-saturated Collagraft and the
adjacent native bone [Fig. 3(d3)], where there was an obvi-
ous gap full of lymphocytes [Fig. 3(e1)]. There were no mac-
rophages detected in the Scaffold group [Fig. 3(F)].
At 6 months, the cartilage defects implanted with SDSC-
based tissue constructs displayed a smooth and glistening
surface [Fig. 4(A)] with expression of chondrogenic markers,
sulfated GAG [Fig. 4(a1)], and collagen II [Fig. 4(a2)]; no colla-
gen I was detectable [Fig. 4(a3)]. In contrast, the ﬁbrinConstruct group Empt
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Fig. 4. Six months after implantation, the Construct group (A) was compared
for sulfated GAG (a1, b1, c1) and immunostaining was for protein expression
200 mm. ThemodiﬁedWakitani Score (D) was used to evaluate the regeneraglue-saturated composite Scaffold group displayed obvious
defects [Fig. 4(B)]. There was no sulfated GAG [Fig. 4(b1)],
less collagen II [Fig. 4(b2)], and more collagen I [Fig. 4(b3)].
Defects in the Empty group were ﬁlled with rough whitish tis-
sue [Fig. 4(C)] without sulfated GAG [Fig. 4(c1)] and with
a mixture of collagen II [Fig. 4(c2)] and collagen I [Fig. 4(c1)].
Six months after transplantation, our results [Fig. 4(D)]
showed that the mean histological score in the Construct
group (5.50 1.38) was better than that of the Empty group
(8.25 0.50). The Scaffold control group (11.14 1.68) had
the highest score indicating the worst outcome.
Discussion
The aim of this study was to evaluate the feasibility of al-
logeneic transplantation for the repair of osteochondraly group Scaffold group
**
C
c1
c2
c3
to the Scaffold group (B) and Empty group (C). Safranin O stain was
of collagen II (a2, b2, c2) and collagen I (a3, b3, c3). All scale bars are
tion of repair tissue and integrationwith the surrounding native tissue.
720 M. Pei et al.: Synovial cell-based cartilage repairdefects using in vitro engineered SDSC-based tissue con-
structs. Our previous study demonstrated that SDSCs pos-
sessed high self-renewing capacity in the clonogenic
growth format and SDSCs could be induced to differentiate
toward adipogenesis, osteogenesis and chondrogenesis22.
In this investigation, conventionally passaged SDSC-based
cartilage tissue constructs were engineered by seeding
a mixture of SDSCs and ﬁbrin glue into PGA meshes fol-
lowed by 1-month incubation in a serum-free culture system
in the presence of growth factor cocktails. Six months after
allogeneic transplantation with premature cartilage, rabbit
femoral condyle full-thickness cartilage defects were resur-
faced with hyaline-like cartilage that displayed good integra-
tion with the surrounding native cartilage.
Recently, stem cell-based tissue engineering has become
a promising and fascinating biological approach for cartilage
repair. Compared to other sources of MSCs, such as bone
marrow11, skeletal muscle28, fat29 and periosteum30, SDSCs
can offer some unique advantages for cartilage tissue engi-
neering10,15e21. In our study, the biodegradable PGA mesh
provides temporary mechanical support31 and the ﬁbrin
glue acts to provide homogenous cell distribution and en-
hance in vitro chondrogenesis as well as potentially blocking
rejection reactions32. Rotating bioreactors provide hydrody-
namic culture conditions, which has been proven as an efﬁ-
cient three-dimensional culture method for cartilage tissue
engineering31. Finally, serum-free deﬁned medium with
a growth factor cocktail can provide SDSCs with chemical
signals for maximum cell proliferation and chondrogenic
differentiation as previously reported22.
After 1-month incubation in a bioreactor system, con-
structs became premature tissue in which expression of sul-
fated GAG and collagen II increased in a time-dependent
manner. As an early chondrogenic marker, collagen I was
still detectable up to 1 month, which is consistent with our
previous studies22,26. Histology data indicated that many
macrophages were found throughout tissue constructs,
contradicting a previous study suggesting that passage 3
monolayer cultured SDSCs formed a homogeneous-
appearing population of ﬁbroblast-like cells negative for
the expression of the macrophage-speciﬁc CD14 gene20.
In contrast, our previous study22,26 suggested that plastic
adhesion could not remove macrophages, presumably
due to macrophages being adhesion cells like ﬁbroblasts.
Negative selection proved to be a fast and simple method
for the puriﬁcation of SDSCs from mixed synovial cells by
minimizing macrophages that might inhibit in vitro chondro-
genesis. However, it is not known if contaminated macro-
phages also affect in vivo cartilage regeneration.
Although implantation of unmodiﬁed MSCs has been
reported to repair cartilage defects in rabbits25, the implan-
tation of uncommitted cells often leads to ﬁbrocartilage for-
mation, indicating that the in vivo environment is not
sufﬁcient to promote chondrogenesis. In contrast, modiﬁed
MSCs with adenovirus mediated-bone morphogenetic pro-
tein (BMP)-2 produced hyaline cartilage-like tissue after im-
plantation in the knee joint, whereas uninfected MSCs
either failed to ﬁll up the defects or formed ﬁbrous tissue
mainly composed of type I collagen3. In our study, SDSC-
based tissue constructs were implanted to repair rabbit
femoral condyle cartilage defects. Three weeks after trans-
plantation, the Construct group showed increasing collagen
II and decreasing collagen I expression. At 6 months, the
Construct group displayed real hyaline-like cartilage with in-
tense expression of sulfated GAG and collagen II as well as
no expression of collagen I, indicating that the damaged
joint environment favors continuous differentiation andmaturation of the implanted premature cartilage tissue,
which is consistent with a previous report33.
Full healing is a complex process and demands differen-
tiation through natural signaling pathways as well as inte-
gration of the regenerated tissue with native tissues.
Since inadequate cartilage integration may ultimately lead
to ﬁbrillation and degeneration of the surrounding tissue34,
one challenge in cartilage repair is to obtain the proper inte-
gration of a mechanically stable interface between repair
and host tissues at the defects35. As documented, MSCs
possess the capacity to engraft successfully into various tis-
sues and organs and maintain long-term stability when in-
fused systematically36. Even more, MSCs infused in the
peripheral circulation have the ability to migrate to a speciﬁc
site of injury. Our data demonstrated that there was good in-
tegration between the implanted tissue and the surrounding
native cartilage 6 months after premature tissue construct
implantation. Cartilage tissue integration can be affected
by the differentiation and remodeling of the transplanted
premature tissue cells. It is dependent on collagen synthe-
sis and cross-linking maturation at the interface37. In this
study, we observed that there was expression of macro-
phages in the implanted constructs at 3 weeks that disap-
peared 6 months after implantation, presumably indicating
macrophages may be involved in the remodeling and inte-
gration of newly formed cartilage.
Since most patients with advanced osteoarthritis are
elderly, many ﬁndings indicate an age-related decrease af-
fecting the amount38, and proliferative potential of MSCs39,
as well as the chondrogenic differentiation capability of
MSCs40. Currently, there are several reports describing
the clinical use of allogeneic donor-mismatched MSCs with-
out host immune rejection or incidence of graft-versus-host
disease41,42. Apart from the possibility of therapeutic use of
allogeneic MSCs in immunocompetent patients without ob-
vious immune rejection, allogeneic MSCs could possibly al-
low therapeutic delivery in a limited time period from
healthier and younger donors. There is no donor site mor-
bidity involved in the use of allogeneic MSCs. Koga et al.
transplanted undifferentiated SDSCs into a full-thickness
articular cartilage defect and did not observe features of im-
mune reactions with the use of allogeneic cells43. Our study
also demonstrated that allogeneic MSCs could survive in
vivo even after they differentiated into chondrocytes in vitro.
The use of allogeneic stem cells could allow manufacturing
of certiﬁed cell batches ready for implantation, circumvent-
ing the limitations and patient-to-patient variability of autolo-
gous cell protocols.
Another concern for cartilage injury treatment is found in
a study that the cartilage became thinner at 24 weeks and
the tidemark moved upward over the majority of the repair
zone, likely due to the dedifferentiation of MSCs to ﬁbrocar-
tilage (marked by the expression of collagen I) or maturation
to hypertrophic cartilage (as indicated by the expression of
collagen X)43. This is a general phenomenon seen in carti-
lage repair of osteochondral defects25,44. Violation of the
tidemark and the subchondral plate presents a problem
with restoration of the original tidemark, which is also
seen in humans and has been described in microfracture45.
In the current study, we could not detect collagen I as well
as collagen X (data not shown) in the newly formed tissue,
indicating a stable hyaline phenotype of the resurfacing
cartilage.
Our study demonstrates that allogeneic SDSC-based tis-
sue constructs can be used to repair femoral condyle osteo-
chondral defects. However, we also observed some
limitations in this study. As a bone substitute, Collagraft
721Osteoarthritis and Cartilage Vol. 17, No. 6was shown to induce long-term inﬂammation that interfered
with osteochondral regeneration resulting in the repair of
the Scaffold group being worse than that of the Empty
group. In addition, the lack of reestablishing normal sub-
chondral bone architecture and the lack of resorption or
remodeling of the Collagraft might result in inferior me-
chanical properties in the newly formed cartilage. Our
long-term goal is to engineer a high-quality cartilage substi-
tute using allogeneic SDSCs for clinical repair of cartilage
defects. Thus, further investigations need to be performed
in the future.
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